Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCALIVA vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
The terminal elimination half-life of obeticholic acid is approximately 24 hours for the parent drug and 3.5 to 5.8 days for its active conjugates (glyco- and tauro-obeticholic acid). This long half-life supports once-daily dosing but indicates that steady-state is reached after about 2 weeks.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Obeticholic acid is metabolized in the liver and intestine via conjugation with glycine or taurine, and subsequently undergoes extensive enterohepatic recirculation. It is not significantly metabolized by CYP450 enzymes. The conjugated metabolites are eliminated in feces.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Following oral administration, approximately 87% of the dose is excreted in feces (primarily as unchanged drug and metabolites) and less than 3% is excreted renally. Biliary excretion is the major route for the parent drug and its conjugates.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Obeticholic acid is approximately 99% bound to plasma proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
The volume of distribution is approximately 6.5 L/kg, indicating extensive extravascular distribution, consistent with its lipophilic nature and high tissue binding, particularly to liver and intestinal tissues.
0.8-1.0 L/kg. Indicates distribution into total body water.
Absolute bioavailability of oral obeticholic acid is approximately 50%, with a range of 30-70% due to first-pass hepatic metabolism and conjugation.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh class A: No adjustment. Child-Pugh class B: Initial dose 5 mg once daily, increase to 10 mg if tolerated. Child-Pugh class C: Contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Safety and efficacy not established in pediatric patients.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
No specific dose adjustment; use caution due to potential for increased exposure and hepatic impairment.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
WARNING: HEPATIC DECOMPENSATION AND LIVER FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR DECOMPENSATED CIRRHOSIS. Patients with Child-Pugh class B or decompensated cirrhosis (Child-Pugh class C) are at increased risk of hepatic decompensation and liver failure when incorrectly dosed. Ocaliva is contraindicated in patients with decompensated cirrhosis (Child-Pugh class C). In patients with Child-Pugh class B, the starting dose is 5 mg once weekly, with dose adjustment based on response and tolerability.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Hepatic decompensation and liver failure in patients with Child-Pugh class B or decompensated cirrhosis,Risk of hepatic decompensation in patients with moderate to severe hepatic impairment,Severe pruritus: dose reduction, antihistamines, or bile acid resins may be considered,Reduction in HDL-C levels; monitor lipid levels periodically,Monitor liver function tests (e.g., bilirubin, INR) and signs of hepatic decompensation
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class C),Known hypersensitivity to obeticholic acid or any component of the formulation
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
No specific food restrictions; however, consistent administration with or without food is recommended. Avoid grapefruit juice as it may increase drug exposure. Limit alcohol consumption to reduce liver stress.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits during organogenesis at doses less than the maximum recommended human dose (MRHD) resulted in embryofetal mortality and malformations. Based on animal data, Ocaliva may cause fetal harm when administered to a pregnant woman. Avoid use during pregnancy, especially in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the fetus.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
It is not known whether obeticholic acid is excreted in human milk. In animal studies, obeticholic acid and/or its metabolites were detected in milk of lactating rats. The M/P ratio is not available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ocaliva, women should not breastfeed during treatment and for 3 weeks after the last dose.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No specific dose adjustments for pregnancy are provided in the labeling. Ocaliva is contraindicated in patients with complete biliary obstruction, and use during pregnancy should be avoided. If use is essential, no data exist to guide dose modifications; pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate empiric dose adjustment, but no formal studies have been conducted.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
OCALIVA (obeticholic acid) is a farnesoid X receptor agonist for primary biliary cholangitis (PBC). Monitor liver function tests closely; dose adjustments needed in moderate to severe hepatic impairment (Child-Pugh B or C). Titrate from 5 mg to 10 mg based on tolerability after 3 months. Contraindicated in patients with complete biliary obstruction. Pruritus is common; consider antihistamines or bile acid binders. Check INR if on warfarin due to potential interaction.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take with or without food, but be consistent with meals to maintain stable drug levels.,Do not stop or change dose without consulting your healthcare provider.,Report severe itching, jaundice, or dark urine immediately.,Avoid alcohol and medications that can harm the liver.,Inform all healthcare providers you are taking this medication.,Attend regular blood tests to monitor liver function and treatment response.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCALIVA vs OFIRMEV, answered by our medical review team.
OCALIVA is a Farnesoid X receptor agonist that works by Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCALIVA and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCALIVA is: 5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCALIVA and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCALIVA is classified as Category C. There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.